NCT02457390

Brief Summary

Laparoscopic ultrasound examination performed during surgery for primary cancer of the colon and rectum (CRC) has been shown to be able to detect liver metastasis that are not recognized by conventional computer tomography (CT scan) prior to surgery. Today most of the colorectal cancer resections are performed by laparoscopy, but robotic technology is gradually developed in an attempt to overcome some of the limitations characterized by laparoscopy. The use of contrast enhanced laparoscopic ultrasound examination (CE-LUS) of the liver during robot-assisted CRC surgery has not been studied, and this despite the fact that it seems technically possible to perform. With this project we will investigate whether CE-LUS associated with robotic surgery for CRC is technically feasible and whether it will be able to detect synchronous liver metastases that have not been detected on the preoperative imaging modalities.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
Completed

Started Jan 2015

Shorter than P25 for not_applicable colorectal-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 5, 2015

Completed
24 days until next milestone

First Posted

Study publicly available on registry

May 29, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
Last Updated

January 26, 2016

Status Verified

January 1, 2015

Enrollment Period

1 year

First QC Date

May 5, 2015

Last Update Submit

January 25, 2016

Conditions

Keywords

contrast enhanced laparoscopic ultrasoundCE-LUSLUSrobot assisted CRC resection

Outcome Measures

Primary Outcomes (1)

  • Detection of synchronous liver metastases with CE-LUS

    3 months

Secondary Outcomes (1)

  • CE-LUS feasibility

    15 minuts

Study Arms (1)

CE-LUS

EXPERIMENTAL

Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases. After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes. The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form.

Procedure: CE-LUS

Interventions

CE-LUSPROCEDURE

To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases. The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure.

Also known as: Sonovue
CE-LUS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients scheduled to robot-assisted CRC resection
  • patients with histologically verified cancer i colon or rectum
  • informed consent
  • patients with minimum age of 18
  • patients without liver metastases

You may not qualify if:

  • patients who have not given informed consent
  • patients with severe heart disease, lung hypertension, or had had a heart attack \< 7 days
  • patients with alcohol or drug abuse.
  • patients with liver metastases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Odense University Hospital

Odense, Odense, 5000, Denmark

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

contrast agent BR1

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Signe B Ellebaek, MD

    Department of Surgery

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 5, 2015

First Posted

May 29, 2015

Study Start

January 1, 2015

Primary Completion

January 1, 2016

Study Completion

January 1, 2016

Last Updated

January 26, 2016

Record last verified: 2015-01

Locations